In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

The Business Research Company's Eylea HD Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...

The Eylea franchise -- including a high-dose (HD) formulation that first earned approval in 2023 -- is facing stiff competition, biosimilar and otherwise. The medicine's sales growth has slowed ...

2.5% for Eylea and 2% for Eylea HD. That's in response to some of the competitive pressures out there and trying to offset some of those pressures." While this is good for revenue growth ...

2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

For instance, during the Class Period, the company mentioned that net sales from Eylea and Eylea HD had grown to $1.49 billion in the U.S. Furthermore, in the quarterly report for the same period ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the Zacks ...